BR112022025551A2 - Tratamento de disfunção atrial - Google Patents

Tratamento de disfunção atrial

Info

Publication number
BR112022025551A2
BR112022025551A2 BR112022025551A BR112022025551A BR112022025551A2 BR 112022025551 A2 BR112022025551 A2 BR 112022025551A2 BR 112022025551 A BR112022025551 A BR 112022025551A BR 112022025551 A BR112022025551 A BR 112022025551A BR 112022025551 A2 BR112022025551 A2 BR 112022025551A2
Authority
BR
Brazil
Prior art keywords
dysfunction treatment
atrial dysfunction
atrial
treatment
patient
Prior art date
Application number
BR112022025551A
Other languages
English (en)
Portuguese (pt)
Inventor
Tamby Jean-Francois
M Edelberg Jay
Howard Takeo Kurio Gregory
Lyle Kelly Cynthia
Yang Chun
Patrick Henze Marcus
L Del Rio Carlos
Lee Anderson Robert
P Sumandea Marius
Ganju Jitendra
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of BR112022025551A2 publication Critical patent/BR112022025551A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
BR112022025551A 2020-06-15 2021-06-14 Tratamento de disfunção atrial BR112022025551A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US202063042512P 2020-06-22 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Publications (1)

Publication Number Publication Date
BR112022025551A2 true BR112022025551A2 (pt) 2023-03-07

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025551A BR112022025551A2 (pt) 2020-06-15 2021-06-14 Tratamento de disfunção atrial

Country Status (13)

Country Link
US (1) US20230233545A1 (https=)
EP (1) EP4164644A1 (https=)
JP (2) JP7832128B2 (https=)
KR (1) KR20230024977A (https=)
CN (1) CN116056703A (https=)
AU (1) AU2021293817A1 (https=)
BR (1) BR112022025551A2 (https=)
CA (1) CA3180943A1 (https=)
CL (1) CL2022003548A1 (https=)
IL (1) IL298885A (https=)
MX (1) MX2022015488A (https=)
TW (1) TW202214241A (https=)
WO (1) WO2021257456A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117379683B (zh) * 2023-12-12 2024-02-27 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234017B1 (en) * 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
AU2018266199A1 (en) * 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료

Also Published As

Publication number Publication date
EP4164644A1 (en) 2023-04-19
JP7832128B2 (ja) 2026-03-17
US20230233545A1 (en) 2023-07-27
TW202214241A (zh) 2022-04-16
MX2022015488A (es) 2023-03-21
CA3180943A1 (en) 2021-12-23
JP2023529502A (ja) 2023-07-10
WO2021257456A1 (en) 2021-12-23
IL298885A (en) 2023-02-01
CL2022003548A1 (es) 2023-06-09
CN116056703A (zh) 2023-05-02
JP2026048841A (ja) 2026-03-17
KR20230024977A (ko) 2023-02-21
AU2021293817A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
BR112022025551A2 (pt) Tratamento de disfunção atrial
CO2020008988A2 (es) Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
MX2021010329A (es) Composicion farmaceutica que comprende empagliflozina y sus usos.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR100560A1 (es) Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
CO2017006032A2 (es) Métodos para tratar la calcificación de tejidos
BR112022015015A2 (pt) Usos terapêuticos de tirzepatida
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.